JP2009178162A5 - - Google Patents

Download PDF

Info

Publication number
JP2009178162A5
JP2009178162A5 JP2009068078A JP2009068078A JP2009178162A5 JP 2009178162 A5 JP2009178162 A5 JP 2009178162A5 JP 2009068078 A JP2009068078 A JP 2009068078A JP 2009068078 A JP2009068078 A JP 2009068078A JP 2009178162 A5 JP2009178162 A5 JP 2009178162A5
Authority
JP
Japan
Prior art keywords
composition
peptide
medicament
amyloid deposition
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009068078A
Other languages
English (en)
Japanese (ja)
Other versions
JP5070236B2 (ja
JP2009178162A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009178162A publication Critical patent/JP2009178162A/ja
Publication of JP2009178162A5 publication Critical patent/JP2009178162A5/ja
Application granted granted Critical
Publication of JP5070236B2 publication Critical patent/JP5070236B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2009068078A 2000-06-20 2009-03-19 神経変性性障害のトランスジェニック動物モデル Expired - Lifetime JP5070236B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21253400P 2000-06-20 2000-06-20
US60/212,534 2000-06-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002503093A Division JP4938956B2 (ja) 2000-06-20 2001-06-19 神経変性性障害のトランスジェニック動物モデル

Publications (3)

Publication Number Publication Date
JP2009178162A JP2009178162A (ja) 2009-08-13
JP2009178162A5 true JP2009178162A5 (enExample) 2011-07-28
JP5070236B2 JP5070236B2 (ja) 2012-11-07

Family

ID=22791418

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002503093A Expired - Lifetime JP4938956B2 (ja) 2000-06-20 2001-06-19 神経変性性障害のトランスジェニック動物モデル
JP2009068078A Expired - Lifetime JP5070236B2 (ja) 2000-06-20 2009-03-19 神経変性性障害のトランスジェニック動物モデル
JP2011132718A Withdrawn JP2011172600A (ja) 2000-06-20 2011-06-14 神経変性性障害のトランスジェニック動物モデル

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002503093A Expired - Lifetime JP4938956B2 (ja) 2000-06-20 2001-06-19 神経変性性障害のトランスジェニック動物モデル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011132718A Withdrawn JP2011172600A (ja) 2000-06-20 2011-06-14 神経変性性障害のトランスジェニック動物モデル

Country Status (13)

Country Link
EP (3) EP1292187B1 (enExample)
JP (3) JP4938956B2 (enExample)
AT (2) ATE499832T1 (enExample)
AU (1) AU2001270377A1 (enExample)
CA (1) CA2407847C (enExample)
CY (1) CY1105122T1 (enExample)
DE (2) DE60118913T2 (enExample)
DK (1) DK1292187T3 (enExample)
ES (1) ES2262662T3 (enExample)
MX (1) MXPA02011516A (enExample)
PT (1) PT1292187E (enExample)
SI (1) SI1292187T1 (enExample)
WO (1) WO2001097607A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100360555C (zh) 2002-04-19 2008-01-09 多伦多大学董事局 治疗阿尔茨海默氏病的免疫学方法及组合物
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
JP4590638B2 (ja) * 2006-03-20 2010-12-01 国立大学法人鳥取大学 家族性筋萎縮性側索硬化症(fals)発症するトランスジェニックマウス
CL2007002908A1 (es) 2007-10-09 2008-05-30 Univ Concepcion Procedimiento electroquimico in vitro para evaluar capacidad neurotoxica de estructuras, principios activos y/o compuestos de interes en celulas vivas y que comprende medir y cuantificar los parametros electricos en membranas expuestas a dichos agreg
CN101918564A (zh) * 2007-11-01 2010-12-15 弗·哈夫曼-拉罗切有限公司 非人类四元转基因动物
WO2010054324A2 (en) * 2008-11-10 2010-05-14 The Regents Of The University Of Colorado, A Body Corporate Methods for treating clinical conditions associated with lipoprotein lipase activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507746A (ja) 1993-10-27 1997-08-12 アテナ ニューロサイエンシズ,インコーポレイティド Swedish変異を有するAPP対立遺伝子を含有するトランスジェニック動物
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0742831B1 (en) * 1994-01-27 2004-09-29 The Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
JP2001517065A (ja) * 1995-06-07 2001-10-02 アセナ ニューロサイエンシーズ,インコーポレイテッド トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法
US5894078A (en) 1996-02-26 1999-04-13 Advanced Bioconcept, Inc. Transgenic mouse expressing C-100 app
WO1999009150A1 (en) * 1996-08-15 1999-02-25 Bayer Corporation Method of introducing modifications into a gene
US5898094A (en) 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Similar Documents

Publication Publication Date Title
JP2017075173A5 (enExample)
EP3563849A3 (en) Combination therapies for the treatment of alzheimer's disease and related disorders
MX2020012932A (es) Nuevos compuestos para diagnostico.
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
EA201890313A1 (ru) Гуманизированные антитела к пироглутаматному варианту бета-амилоида
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
PH12013500615A1 (en) Phosphospecific antibodies recognising tau
EP2683382A4 (en) DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY
EP2504036A4 (en) DEVICE FOR STEP-BY-STEP COMPRESSION FOR THE TREATMENT OF CIRCULAR DISEASES
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
EA200870556A1 (ru) Комбинированная терапия в лечении эпилепсии и родственных расстройств
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
JP2015501783A5 (enExample)
EP2306956A4 (en) RANDOM VIBRATION FOR THE TREATMENT OF BLEACHING TROUBLES
EP2282795A4 (en) TREATMENT OF RESPIRATORY DISEASES
GT201100283A (es) Anticuerpos humanizados especificos de la forma protofibrilar del péptido beta-amiloide
EP2822563A4 (en) INHALATION OF STICK OXIDE FOR THE TREATMENT OF RESPIRATORY DISEASES
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
JP2011520900A5 (enExample)
WO2011072257A3 (en) Amyloid binding agents
EP2438923A4 (en) COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF OBSERVATION-BASED ILLNESSES BY THE ACTIVATION OF AMPK AND WITH 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURANLIGNANES AS ACTIVE SUBSTANCES
ES2489297B1 (es) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
CN110114079A (zh) 一种预防和治疗肥胖症的方法和药物
EP2890370A4 (en) MEANS FOR THE TREATMENT OF ADIPOSITAS, DIABETES AND RELATED DISEASES